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CONTINUING EDUCATION
Anemia and the Role of the Pharmacist

by Ashlie Kucera, Pharm.D. Candidate Class of 2015; Bethany Smith, Pharm.D. Candidate Class of 2015;
Laura Tsu, Pharm.D., BCPS; Midwestern University College of Pharmacy – Glendale
Goal:
This home-study CPE has been developed to educate
pharmacists and pharmacy technicians about the various
types of anemia and their treatments.
Objectives:
At the conclusion of this lesson, successful participants should
be able to:
1. Identify signs and symptoms of anemia
2. Differentiate between types of anemia and their etiology
3. Perform patient counseling for oral iron therapy, including
dosing, drug interactions and side effects
4. List goals of iron therapy
5. Name food sources rich in iron, folic acid and/or vitamin
B12
6. Describe treatment of folic acid and vitamin B12 deficiency
anemias
Introduction
Anemia, a condition characterized by decreased hemoglobin levels and an insufficient ability to oxygenate the body, is
one of the most common blood disorders in the world.
Globally, it affects over 1.6 billion people; roughly 25% of the
world population.1
In healthy individuals, oxygen is adequately transported
throughout the body via hemoglobin (Hgb), a protein found
in red blood cells (RBCs). RBCs require several nutrients to
function properly including iron, folate and vitamin B12. A
deficiency in any of these nutrients, alteration of morphology
of the cell, increased RBC destruction or excessive blood loss
can result in anemia.2
There are numerous causes of anemia including
malnutrition, chronic conditions, pregnancy and drug-induced
anemia.3 Additional risk factors for anemia include folic acid
deficiency, vitamin B12 and autoimmune disorders (Table 1.1).
Healthy patients with anemia may be asymptomatic if
their hemoglobin levels decrease slowly over time. Presentation with acute anemia may present as tachycardia or hypotension, while chronic conditions often present with more
generalized symptoms like fatigue, weakness or pale skin (Table

1.2).4,5

Diagnosis
Although diagnosing anemia may be relatively straight
forward, a thorough workup is generally required to identify
the etiology of the disorder. Since there are many different
causes of anemia it is important to identify the origin of the
disorder so that it may be treated correctly and can be
prevented in the future. Usually the assessment begins with

a detailed history of the patient, including information such as diet and lifestyle, medical history, family
history, current medications and religious practices
that may influence their diet.6 Next, a physical exam is
performed and several laboratory tests are completed.6 Laboratory tests commonly used for the
diagnosis of anemia include a complete blood count
(CBC), iron studies, and serum nutrient levels.6,7,8
Table 1.3 contains common laboratory tests used to
diagnose anemia and explains what each test assesses.
There are three broad categories of anemia which are
differentiated by their mean cell volume (MCV) which
measures the size of the RBCs. As depicted in Table
1.3, normal values for MCV range from 80-100 fL/
cell.9 Macrocytic anemias, also known as megaloblastic
anemias, have a MCV level greater than these values,
and include folic acid deficiency anemia, vitamin B12
deficiency anemia and pernicious anemia.10 Microcytic
anemias have decreased MCV values and include iron
deficiency anemia. Finally, normocytic anemias have
MCV values that are within normal limits, and the
RBCs present in these patients are generally
unaffected. These anemias are caused by acute blood
loss or abnormal blood cell production, such as
aplastic anemia or anemia from chronic renal
disease.4,11,12 Assessment of a MCV value provides a
general classification of the anemia and gives the
provider a better idea of what potential causes may
be.
Microcytic Anemias
Iron Deficiency Anemia:
Iron deficiency anemia, a microcytic anemia6, is
the most common type of anemia in the world.3 As
indicated by its name, iron deficiency anemia is the
result of insufficient iron in the blood. There are
various causes of iron deficiency, such as insufficient
consumption in the diet, malabsorption, heavy
menstruation, pregnancy, dialysis and gastrointestinal
inflammatory disorders.3,6 On presentation, this type
of anemia may differentiate from others with
specific signs and symptoms. These signs include
tongue soreness or smooth appearance, pica,
phagophagia, and/or dry mouth.4 Table 2.1 contains
symptoms of specific anemias. Suspicion of iron deficiency anemia is verified via analysis of iron indices
and of other labs included in Table 1.3. Patients with
iron deficiency anemia will have decreased serum iron,
ferritin and transferrin saturation (TSAT) levels and an
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increased total iron-binding capacity (TIBC).7 Additionally,
patients with anemia will frequently show hemoglobin
levels below 13 g/dL in men and 12 g/dL in women.1
Once a specific diagnosis of iron deficiency anemia has
been determined, there are several methods of treatment
that can be attempted. Generally, mild iron deficiency can
be treated on an outpatient basis with oral iron replacement therapy, with a goal of 200 mg of elemental iron per
day. There are currently four oral iron supplements available
on the market commonly used for treatment: ferrous
gluconate, ferrous sulfate, ferrous fumarate, and
polysaccharide iron complex. Table 2.2 describes these oral
iron products and their elemental iron content. Of these
four, ferrous sulfate is prescribed most commonly and is
likely the oral therapy encountered most often in
community pharmacies.3
To ensure that patients get maximum benefit out of oral
iron therapy, medication counseling should be performed.
Regimens of iron supplements should be divided into two to
three doses daily. These supplements should be taken on an
empty stomach, an hour before meals or two hours
following a meal. Oral iron has been found to have
increased absorption when taken with ascorbic acid, so it is
often recommended that these supplements be taken with
a glass of orange juice.3
Side effects of oral iron therapy are mostly inflicted on
the gastrointestinal (GI) tract, and include abdominal pain,
nausea, constipation, heartburn and dark stools. It is
because of this GI upset that one-time daily dosing should
be avoided.13,14,15,16 If the patient experiences GI side
effects that are intolerable, it is recommended that the
supplements be taken with orange juice and/or food. There
are several drug-drug interactions of oral iron supplements
that the pharmacist should be cautious of when filling a
prescription. Table 2.3 lists these interactions.
To assess response to oral iron therapy labs will need
to be monitored. Reticulocyte count, an assessment of the
production of new RBCs, should increase within seven to
ten days. Hemoglobin (Hgb) and hematocrit (Hct) should
also be tracked with an expected increase in Hgb of 1g/dL
per week and at least 2g/dL total by three weeks of
therapy.6
Educating patients about dietary sources of iron is an
important intervention for both treatment of deficiency and
for preventing future occurrence of anemia. Meat is a good
source of iron, including red meat, chicken, fish and organ
meats (i.e. liver). Other sources include beans, green leafy
vegetables and enriched breakfast cereals. These non-meat
sources contain “non-heme” iron, which have a lower rate
of absorption than “heme” iron found in meat. Therefore,
it is often difficult for vegetarians to achieve recommended
levels of intake of iron. In this patient population,
iron-containing dietary supplements may be considered for
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prophylaxis.17
In severe cases of iron deficiency anemia, if the
patient is unable to tolerate oral therapy or if there is
an inadequate response to oral therapy, parenteral iron
therapy is indicated.3 There are currently four parenteral
iron products commonly used: iron dextran, iron sucrose
and sodium ferric gluconate and ferric carboxymaltose.
Table 2.4 describes these products and their
recommended doses.
All parenteral iron products have a risk of
anaphylaxis, with the highest risk associated with iron
dextran. Due to this high risk, a test dose is required
prior to administering iron dextran.18 Other adverse
effects of intravenous iron include arrhythmias,
arthralgia, hypotension, flushing and prurtitis.18,19,20,21
Two formulations, iron sucrose and sodium ferric
gluconate, are only FDA approved for the treatment
of anemia associated with chronic kidney disease
(CKD).19,20
Macrocytic Anemias
Vitamin B12 Deficiency and Pernicious Anemias:
Vitamin B12 deficiency anemia, a macrocytic
anemia, is one of the most common types of anemia in
the United States.22 A deficiency of vitamin B12 can be
caused by several factors, including diet, malabsorption,
alcoholism, or decreased stomach acidity.23 Certain
medications can also lead to deficiency such as proton
pump inhibitors and metformin. A severe form of
vitamin B12 deficiency is called pernicious anemia.
Pernicious anemia is a specific type of anemia that is
caused by autoimmune destruction of gastric parietal
cells. In healthy individuals these cells produce intrinsic
factor (IF) which is required to bind and absorb dietary
vitamin B12. When autoimmune destruction of the
gastric parietal cells takes place, vitamin B12 can no
longer be absorbed and deficiency occurs.24
Specific signs and symptoms differentiate these
two types of anemia from others such as numbness,
parasthesias and gait disturbances.23 See Table 2.1 for
additional symptoms. Development and myelination of
the central nervous system requires vitamin B12. Thus,
severe deficiency can result in the presence of
debilitating neurologic complications.24 Laboratory
findings to confirm these types of anemias are
decreased serum vitamin B12 levels and IF, normal
folate levels, and increased serum methylmalonic acid
and total homocysteine levels.8
Once vitamin B12 deficiency anemia has been confirmed, early treatment is important since neurological
sequelae can be irreversible if not treated in a timely
manner. Treatment options include replacement therapy
in a variety of dosage forms, most commonly intramus-
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cular or oral formulations. Generally, parenteral replacement is the preferred method since approximately 10% of
these doses are absorbed compared to only 0.5-4% of oral
doses.22 For this reason lower doses of vitamin B12 can be
given when administered intramuscularly. In order for oral
therapy to be effective, high doses must be given. Table 3.1
contains recommended dosing for both oral and parenteral
vitamin B12 therapies.22, 24
Lab values and symptoms should be monitored to
determine response to therapy. Neurological symptoms
and megaloblastic cells should resolve within a few days, in
general. An increase in H/H should be noted after about one
to two weeks of therapy.24 Replacement therapy is usually
long term for patients without pernicious anemia. For those
diagnosed with pernicious anemia, lifelong therapy will be
required.22 CBC and serum vitamin B12 levels should be
monitored over time, at least 1-2 months after initiation
of therapy and 3-6 months thereafter.22,24 Side effects of
replacement therapy include dizziness, headache, anxiety
or nausea.25 Increased consumption of foods rich in vitamin B12 can help alleviate deficiency and prevent future
episodes. Meat, fish, poultry, eggs and dairy products are
examples of these. As noted previously, increased
consumption of nutrients such as this can be difficult for
vegetarians and prophylactic dietary supplementation may
be indicated.22
Folic Acid Deficiency Anemia:
Folic acid deficiency anemia is another common type
of anemia in the United States. This macrocytic anemia is
caused by diet, alcoholism, pregnancy and lactation, and
dialysis. Folic acid deficiency can also be drug-induced and
may be due to the use of sulfasalazine, methotrexate,
phenytoin, triamterene, or trimethoprim.3,8,10
Unique signs and symptoms of folic acid deficiency are
irritability, personality changes, and memory impairment.17
Refer to Table 2.1 for additional symptoms. Confirmation of
this deficiency anemia is obtained by lab values of
decreased folate levels, and normal vitamin B12, IF and
methylmalonic acid levels.10 Treatment of this anemia is
usually accomplished with oral replacement therapy. Table
3.2 describes common dosing regimens for folic acid
deficiency anemia. Side effects of replacement therapy are
generally mild and include malaise, rash and flushing.26
Green leafy vegetables, citrus fruits, dairy and grains are
examples of dietary sources rich in folate.17
Normocytic Anemias
Acute Blood Loss Anemia:
Hemorrhage and acute blood loss results in anemia due
to RBC volume depletion. Acute blood loss can occur with
GI bleeds, trauma or surgery. Symptoms of acute blood
loss are rapid blood pressure decline and dizziness.5 This is
CONTINUING EDUCATION

categorized as a normocytic anemia since the existing
RBCs are largely unaffected. Hemoglobin and Hematocrit (H/H) are surrogate makers for this type of anemia.
An elevated reticulocyte count in also noted in these
patients.17 Refer to Table 1.3 for normal values of these
labs. Treatment for acute blood loss anemia is generally
a blood transfusion if the loss is substantial, in addition
to stopping the source of the bleed.5
Chronic Blood Loss Anemia:
Anemia in chronic blood loss results from a slow
downward trend of RBC volume. Conditions such as
stomach ulcers, diverticulitis, cancers or heavy
menstrual bleeding are associated with this type of
anemia. Symptoms include fatigue, shortness of breath
or paleness.5 Lab values are similar to those of acute
blood loss and display decreased H/H values.17
Treatment with blood transfusions for this type of
anemia may not be indicated; however supplementation
with iron therapy may be used for several months.5
Aplastic Anemia:
Aplastic anemia occurs when a bone marrow
disorder results in a decreased production of RBCs.
Other causes of this type of anemia include radiation
and chemotherapy, exposure to toxins, autoimmune
disorders, HIV, Epstein-Barr virus, parvo and pregnancy.12 Some medications may also cause aplastic anemia
such as phenytoin, carbamazepine, chloramphenicol,
felbamate and quinine.17 Symptoms of this type of
anemia include fatigue, rapid or irregular heart rate,
frequent infections, unexplained bruising, nosebleeds
and bleeding gums, and rash.12 Lab values for aplastic anemia show decreased reticulocyte count, white
blood cells (WBCs) and platelets.17 For a confirmatory
diagnosis a bone marrow biopsy is required. Blood
transfusions, stem cell transplant or pharmacotherapies
are treatments for this type of anemia.12 Immunosuppresants such as cyclosporine, methylprednisolone, or
antithymocyte globulin are examples.12 Bone marrow
stimulants including filigrastim and epoetin alfa can
also be used as adjunctive therapy with immunosuppresants.12 Therapy with antivirals and antibiotics may
be warranted to prevent infections in these vulnerable
patients.
Anemia of Chronic Kidney Disease:
Patients with chronic kidney disease often exhibit
anemia due to decreased production of erythropoietin
by the kidneys. These patients often suffer from weakness, inability to concentrate, chest pain, fatigue, and
headache.11 Heart failure and tachycardia are common
complications of this type of anemia.11 Decreased reticulocyte count and normal or increased WBCs and
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platelets are often seen in this patient population.17
Additional testing may include H/H, ferritin and TSAT
levels.11,17 Common treatments involve erythropoietin, iron
supplementation, blood transfusions, and vitamin B12 and
folate supplementation.11

Acute

Chronic

Tachycardia

Asymptomatic

Palpitations

Fatigue

Angina

Weakness

Hypotension

Headache

Other Anemias
Another form of anemia is anemia of chronic disease.
Also called “anemia of inflammation”, this disorder is due to
conditions such as rheumatoid arthritis, lupus, cancer, HIV,
and inflammatory bowel disease.27 When severe, this type
of anemia resembles iron deficiency anemia.27 Symptoms
are general, see Table 1.2 for a list. Suspected cases of this
type of anemia are generally confirmed by detection of an
increased level of cytokines. Other lab values include
decreased MCV and TIBC, increased TSAT, and normal/elevated serum iron and ferritin.17,27 Treatment options for
anemia of chronic disease include blood transfusions, erythropoietic agents, and iron therapy if deficiency is present.27
There are several other types of anemia which are less
common. Two examples of these are sickle cell anemia
and myeloplastic anemia which will not be discussed in the
article.

Light-headedness

Sensitivity to cold

Shortness of breath

Pale and yellow skin

"Whooshing" sound in ears
Table 1.2. General signs and symptoms of anemia.
CBC
Hgb

Iron
Studies
M: 14-17
g/dL

RBC
Indices

Serum
Iron

M: 46-160
mcg/dL

F: 12-15 g/dL
Hct

M: 42-50%
F: 36-45%

RBC
count

M: 4.5-6 x
106 cell/mL
F: 4-5 x 10
cell/mL

Pharmacist’s Role
The pharmacist has a critical role in the treatment of
patients with anemia. Pharmacists can assist patients with
therapy management, particularly in areas of iron administration, dietary recommendations, drug interactions with
oral iron, and medications that can exacerbate conditions.
As pharmacists, we should also be aware of the signs and
symptoms of anemia in order to assess efficacy of treatment
and refer those patients who need to seek medical
attention. Pharmacists can utilize their extensive
pharmacological knowledge to increase positive outcomes
in our patients.

Other

MCV

80-100
fL/cell

Vitamin B12

180-660 pg/mL

F: 30-160
mcg/dL
Serum
Ferritin

12-300 ng/mL

MCH

27-33
pg/cell

Plasma Folate

3.4-12.4 mcg/L

TIBC

220-420 mcg/dL

MCHC

33.435.5%

Reticulocyte
count

M: 0.5-1.5%

TSAT

30-50%

F: 0.5-2.5%

6

RBC
distribution
width

14.5-15.5%

Schilling test
(intrinsic factor)

10% excretion of
radiolabeled B12

Methylmalonic
acid

0.08-0.56 mcmol/L

Homocysteine

4-17 mcmol/L

Table 1.3. Common anemia laboratory parameters and normal ranges.
CBC=complete blood count
Hgb=hemoglobin
Hct=hematocrit
RBC=red blood cell
M=male
F=female
TIBC=total iron binding capacity
TSAT=transferritin saturation
MCV=mean cell volume
MCH=mean cell hemoglobin
MCHC=mean cell hemoglobin concentration

Iron Deficiency Vitamin B12 Deficiency

Folate Deficiency

Sore mouth

Numbness/parasthesia

Irritability

Smooth tongue

Imbalance (gait disturbance)

Personality changes

Pica

Personality changes

Depression

Pagophagia

Swollen/inflamed tongue

Memory impairment

Reduced saliva

Depression

Mouth sores

Table 2.1. Signs and symptoms for specific types of anemia.

Chronic Conditions

Drug-induced

Miscellaneous

Crohn's Disease

Aspirin

Folic acid deficiency

Ulcerative colitis

NSAIDS

Vitamin B12 deficiency

Rheumatoid Arthritis

PPIs

Pregnancy

Autoimmune disorders

H2RAs

Lactation

Cancer

Antacids

Heavy menstruation

Liver disease

Trimethoprim

Reduced stomach acid

Thyroid disease

Triamterene

Poor diet

Chronic Kidney Disease

Methotrexate

Malnutrition

Dialysis

Phenytoin

Infection

Alcoholism

Sulfasalazine

Children

Agent

Percent Elemental
Iron

Elemental Iron/Dose Form

Ferrous gluconate

12%

39 mg/325 mg tablet

Ferrous sulfate

20%

37 mg/300 mg tablet
65 mg/325 mg tablet
60 mg/300 mg tablet
44 mg/5 mL elixir

Decrease iron absorption

Medications affected by
iron

Gastric acid suppressants

Levodopa/methyldopa

(antacids, PPIs)
Ferrous fumarate

33%

33 mg/100 mg tablet

Levothyroxine
Cholestyramine

Polysaccharide-iron
complex

100%

150 mg/capsule
50 mg/tablet

Bisphosphonates
Tetracycline/doxycycline
Fluoroquinolones

Table 2.2. Oral iron products.

Table 1.1. Risk factors for anemia.
PPIs=proton pump inhibitors
H2RAs=histamine 2 receptor antagonists

Tetracycline/doxycycline
Table 2.3. Drug-drug interaction with oral iron products.
PPIs=proton pump inhibitors
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Agent

Recommended Dosing

Iron sucrose

Non-dialysis: 200 mg administered on 5 different occasions within 14 days
totaling 1000 mg in 14 days

Iron dextran

Dose (mL) = 0.0442 (desired Hgb - observed Hgb) x LBW + (0.26 x LBW), with
desired hemoglobin at 14.8 g/dL and LBW= lean body weight; test dose of 0.5 ml
should be given

Sodium ferric gluconate

125 mg elemental iron per dialysis session. Most patients will require a
cumulative dose of 1 g elemental iron over approximately 8 sequential dialysis
treatments to achieve a favorable response

Ferric carboxymaltose

<50 kg: 15 mg/kg elemental iron on day 1; repeat dose after at least 7 days
(maximum: 1500 mg elemental iron per course). May repeat course of therapy if
anemia reoccurs
≥50 kg: 750 mg on day 1; repeat dose after at least 7 days (maximum: 1500 mg
per course). May repeat course if anemia reoccurs

Agent

Dosing

Adverse Drug Reactions

Oral B12

1000-2000 mcg/day

IM B12 injections

Start with 8-10 loading

Nausea, nervousness, dizziness, headache,
edema, itching, diarrhea, rhinitis, dysnpea,
peripheral vascular thrombosis, avoid if
allergic to cyancobalamin or cobalt

Vitamin B12:

doses of 1000 mcg several
times 1 week (if severe),
taper to 1000 mcg /month
Table 3.1. Recommended dosing for vitamin B12.
IM=intramuscular

Table 2.4. Parenteral iron products.

Agent

Dosing

Adverse Drug Reactions

Folic acid

Adults: 0.4 mg/day

(PO, IV, IM, SQ)

Pregnancy: 0.8/day

Malaise, flushing, rash, erythema,
bronchospasm

Folate:
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